Bonum Therapeutics
Bonum Therapeutics is focused on a proven technology that utilizes allosteric regulation to create targeted, highly active, and less toxic medicines.
Work at Bonum Therapeutics in HR or recruiting? Claim this page
Headcount trend
Bonum Therapeutics went from 25 employees in Oct 2024 to 22 in Sep 2026. Apr to Sep 2026: 0 people joined, 3 left.
Funding rounds
| Date | Round | Money raised | No. | Investors |
|---|---|---|---|---|
| Nov 2022 | Series A | $93M | 5 | |
| Dec 2021 | Seed | $1.2M | 4 | |
| Dec 2021 | Series B | $8.8M | 4 | |
| Nov 2018 | Series A | $22.3M | – | – |
Org structure
Headcount by department
Peer reviews
Worked with someone at Bonum Therapeutics?
Anonymous peer reviews on OffTheRecord
Similar companies
Bonum Therapeutics FAQ
How many employees does Bonum Therapeutics have?
Bonum Therapeutics has about 22 employees, unchanged over the 3 months to Sep 2026.
What is Bonum Therapeutics's revenue per employee?
Bonum Therapeutics makes about $266K in revenue per employee, based on $5.85M annual revenue and 22 employees.
How much funding has Bonum Therapeutics raised?
Bonum Therapeutics has raised $125.33M in total funding; its latest round was Series A in Nov 2022.
Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.